Exploiting innate immunity for cancer immunotherapy

Table 8 Tumor-associated neutrophil (TAN)-targeted cancer therapies

Classification	Target	Agents	Representative clinical trials	Cancer types	Phase
Inhibiting TAN recruitment into the TME	CXCR1/2	Reparixin	NCT02370238	TNBC	2
		Navarixin	NCT03473925	Solid tumors	2
		SX-682	NCT04574583	Solid tumors	1/2
	CXCR2	AZD5069	NCT03177187	Prostate cancer	1/2
	CXCL8	HuMax-IL8	NCT02536469	Solid tumors	1
	CXCR4	BL-8040	NCT02826486	Pancreatic adenocarcinoma	2
		BMS-936564	NCT01120457	Leukemia	1
		MSX-122	NCT00591682	Solid tumors	1
		Plerixafor	NCT01236144	Leukemia	1/2
		MB1707	NCT05465590	Solid tumors	1
Increasing the antitumor activity of TANs but undermining their protumor capabilities	PD-1/PD-L1	Nivolumab	NCT02713867	NSCLC	3
		Pembrolizumab	NCT02555657	TNBC	3
		Atezolizumab	NCT03125902	TNBC	3
	CD47/SIRPα	Hu5F9-G4	NCT03922477	Leukemia	1
		TTI-621	NCT02663518	Hematologic and solid malignancies	1
		CC-90002	NCT02641002	Leukemia	1
	COX-2	Celecoxib	NCT03026140	Colon cancer	2
	S100A8/A9	Tasquinimod	NCT01234311	Prostate cancer	3
Reprogramming TAN toward the antitumor phenotype	TGF-β	M7824	NCT03631706	NSCLC	3
		BiTP	NCT05028556	Solid tumors	1
		SHR-1701	NCT05179239	Cervical cancer	3
	NAMPT	ATG-019	NCT04281420	Hematologic and solid malignancies	1

NSCLC non-small cell lung cancer, TNBC triple-negative breast cancer, TAN tumor-associated neutrophil, TGF-β transforming growth factor β, NAMPT nicotinamide phosphoribosyltransferase, COX-2 cyclooxygenase-2, TME tumor microenvironment

ISSN: 1476-4598